X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of patients with advanced non-small cell lung cancer harboring a KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,800.0 million Upfront Cash: $5,800.0 million
Deal Type: Acquisition January 23, 2024
Details:
The collaboration aims to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Adagrasib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Kura Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2023
Details:
Through the acquisition, BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of patients with advanced non-small cell lung cancer harboring a KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,800.0 million Upfront Cash: $5,800.0 million
Deal Type: Acquisition October 08, 2023
Details:
Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated for colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: MGCD516
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
MRTX1133 is an investigational, highly potent, selective and reversible inhibitor of KRASG12D that is optimized to sustain near complete target inhibition. It is currently being investigated for KRASG12D-driven cancers.
Lead Product(s): MRTX1133
Therapeutic Area: Oncology Product Name: MRTX1133
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated for colorectal cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Krazati (adagrasib), is being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors. Lung cancer is one of the world’s most widespread cancers.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qiagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Mirati has risen to meet one of the most challenging mutations in cancer research by developing KRAZATI, a highly selective and potent oral small-molecule inhibitor of KRASG12C.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: MGCD516
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
